Background. The clinical significance of blood lead levels (BLLs) in chronic peritoneal dialysis (CPD) patients was undetermined prior to this study. Methods. A total of 315 patients on CPD were included in this 18-month prospective study. BLLs measured at baseline were categorized according to a BLL tertile of high (>8.66 μg/dL), middle (5.62-8.66 μg/dL) and low (<5.62 μg/dL) for cross-sectional analyses. Mortality and cause of death were recorded for longitudinal analyses. Results. At baseline, patients with high BLLs had a trend of higher parathyroid hormone and lower residual renal function than patients in other groups. Stepwise multiple regression analysis found that parathyroid hormone positively correlated and residual renal function negatively correlated with logarithmic-transformed BLLs in CPD patients after other confounders were adjusted. At the end of follow-up, 37 (11.7%) patients had died. KaplanMeier analysis showed that patients with high BLLs had greater mortality than those with middle and low BLLs (P = 0.008). Cox multivariate analysis showed that, using the low BLL group as the reference, basal high BLLs (hazard ratio [HR] = 3.745, 95% confidence interval [95% CI] = 1.218-11.494, P = 0.001) and middle BLLs (HR = 1.867, 95% CI = 1.618-2.567, P = 0.001) were associated with increased HR for all-cause mortality for CPD patients. There is a significant trend (P < 0.001) of HR for mortality trend tests among the three study groups. Conclusions. BLLs are associated with residual renal function and hyperparathyroidism and are related to increased HR for all-cause 18-month mortality in CPD patients.
Introduction
Lead is known for its toxic effects on human beings. Previous studies have suggested that blood lead levels (BLLs) are associated with all-cause and cardiovascular-cause mortality in the general population [1, 2] . A recent epidemiological investigation demonstrated that adults with low BLLs (<10 μg/dL) still had high cardiovascular-cause mortality rate in those with BLLs >3.61 μg/dL and <10 μg/dL [3] . Moreover, BLLs accelerate age-related renal function impairment in the general population [4] [5] [6] . Recent investigations have also shown that environmental exposure to lead is related to progressive renal insufficiency in patients with [7] and without diabetes [8] , and chelation therapy may retard disease progression in these patients [8] [9] [10] . In patients with end-stage renal disease (ESRD), lead has been shown to accumulate in bone and increase BLLs in maintenance haemodialysis (MHD) patients [11, 12] . Additionally, some clinical studies [12, 13] have demonstrated associations between BLLs and haemoglobin levels, diastolic blood pressure and intact parathyroid hormone (iPTH) levels in MHD patients, although the related variables were not adjusted. A recent work [14] indicated that BLLs are associated with inflammation, malnutrition and mortality in a relatively small group of diabetic MHD patients. However, the clinical significance of BLLs in chronic peritoneal dialysis (CPD) patients remains unknown.
Recent evidence from clinical studies [15] [16] [17] [18] has shown that the risk factors associated with short-term mortality besides malnutrition-inflammation complex syndrome are renal osteodystrophy and residual renal function for CPD patients. Correcting these risk factors may reduce the mortality rate for long-term dialysis patients [19] . Therefore, it is important to identify correctable factors associated with residual renal function, renal osteodystrophy, inflammation or malnutrition in patients undergoing chronic dialysis. However, the correlation of BLLs with mortality, residual renal function, renal osteodystrophy, inflammation and/or malnutrition in CPD patients remains unknown.
We, therefore, conducted a cross-sectional, prospective 18-month investigation to study the relationship between BLLs and health status by clinically examining CPD patients. Moreover, we analyzed whether BLLs pose a mortality risk to these patients.
Materials and methods
This clinical study followed the Declaration of Helsinki and was approved by the Medical Ethics Committee of Chang Gung Memorial Hospital (CGMH), Taipei, Taiwan.
Patients
All study patients were recruited from the Peritoneal Dialysis Center of Lin-Kou Medical Center, CGMH. Only patients undergoing CPD for more than 6 months were enrolled, after excluding individuals with a history of occupational exposure to heavy metals or metal intoxication, those living in metal-contaminated areas, those with malignancies and those <18 years of age. All patients were prospectively followed up for 18 months. The PD prescription for each patient was based on the peritoneal membrane characteristics as determined by the peritoneal equilibration tests, with intermittent therapies used primarily for patients with high transport characteristics and continuous therapies for those with average or low transport characteristics. Fifty-five patients were treated with automated PD and 260 patients underwent continuous ambulatory PD, including one patient with three exchanges per day, 172 patients with four exchanges per day (58 with 1.5 L/ exchange, 108 with 2 L/exchange and 6 with 2.5 L/exchange), 22 patients with five 1.5-L exchanges and 65 patients with five 2-L exchanges per day. Low-calcium (1.5 or 1.25 mmol/L), icodextrin-based (7.5 g/dL) or standard dialysate containing glucose (Na, 135 mmol/L; lactate, 35 mmol/L; Ca, 1.75 mmol/L) were used according to the patients' peritoneal transport characteristics and serum calcium levels to maintain adequate ultrafiltration and normal calcium levels. Dialysis prescription aimed at obtaining a total Kt/V of at least 1.8 per week.
Primary renal disease and comorbid conditions were determined after in-depth review of medical records, including history and physical examination, progress notes, discharge summaries, consultations and biopsy results. Patients with diabetes were defined as those with a history of diabetes diagnosed by a physician or any two subsequent fasting glucose levels being >126 mg/dL. The presence of cardiovascular disease (CVD)-including cerebrovascular disease, coronary artery disease, congestive heart failure and peripheral vascular disease-was recorded. History of smoking, alcohol consumption and drug use was also recorded.
Measurement of lead
To ensure that the patients were not exposed to dialysate lead contamination during PD, we gathered at least two samples in lead-free plastic bottles containing dialysate from 2-L PD dialysate bags before and 4 h after abdominal retention in 13 patients. BLLs were measured using a previously described method [14, 30] . Briefly, 900 μl of modifier solution of NH 4 H 2 PO 4 + hNO 3 (2 ml) + Triton X-100 in deionized water and 100 μl of whole blood or 100 μl of modifier solution and 900 μl of dialysate were added to a 1.5-ml Eppendorf vessel that was immediately shaken. After overnight storage in a refrigerator, the vessels were warmed to room temperature and then whirl-mixed for 5-10 s. The diluted blood sample was transferred to graphite furnace sampler cups. Moreover, lead levels in the acid-digest samples were measured by electrothermal atomic absorption spectrometry (SpectrAA-200Z; Varian, Palo Alto, CA, USA) with Zeeman background correction and an L'vov platform. We used both internal and external quality-control procedures and achieved consistently satisfactory results. A certified commercially prepared product (Seronorm Trace Elements; Sero AS, Billingstad, Norway) was used to determine intra-batch accuracy and to ensure inter-batch standardization. The coefficient of variation for lead measurement was <5.0%. External quality control was maintained through participation in the National QualityControl Program conducted by the Taiwanese government. BLLs were classified into three equal groups: low (BLLs < 5.62 μg/dL), middle (BLLs = 5.62-8.66 μg/dL) and high (BLLs > 8.66 μg/dL). As most blood lead exists in red blood cells, patients with ESRD have anaemia, and the previous work performed the correction in patients with MHD [12] , BLLs were also corrected with haemoglobin (C-BLL) [12] to prevent possible bias, as detailed: C-BLLs = initial lead levels × 14/initial haemoglobin levels (in grams per decilitre) in men and initial lead levels × 12/initial haemoglobin levels (in grams per decilitre) in women. The C-BLLs were also stratified into three equal groups: low (C-BLLs < 7.57 μg/dL), middle (CBLLs = 7.57-11.99 μg/dL) and high (C-BLLs > 11.99 μg/dL).
Laboratory parameters
All laboratory values, including blood cell counts, biochemical data, normalized protein nitrogen appearance (nPNA), peritoneal transport characteristics, residual renal creatinine clearance (Ccr), peritoneal Ccr, standard total Ccr (normalized to body surface area), residual renal Kt/V urea, peritoneal Kt/V urea and total Kt/V urea, were measured by automated and standardized methods. All blood samples were collected in the morning after at least 12 h of fasting. Serum albumin, creatinine, cholesterol and triglyceride, white blood cell (WBC) counts, haemoglobin, serum ferritin and transferrin saturation levels were assayed and recorded. Serum calcium was corrected for serum albumin according to the following formula: Corrected calcium (in milligrams per decilitre) = serum calcium (in milligrams per decilitre) + 0.8 × [4.0 − serum albumin (in grams per decilitre)]. All other markers were measured via standard laboratory methods using an automatic analyzer.
Follow-up
Patients were followed up for 18 months after the initial assessment. Every death during the follow-up period was reviewed and assigned an underlying cause by physicians not involved in this study. Cardiovascular-cause death is defined as the event of arrhythmia, acute or sub-acute ischemic heart disease, congestive heart failure, sudden death, intra-cerebral haemorrhage, occlusion of cerebral arteries, vascular interventions, etc.
For patients who died in the hospital, cardiovascular or infection events during follow-up were obtained from discharge diagnosis and death certificates in hospital charts. In the case of an out-of-hospital death, family members were interviewed by telephone to ascertain fully the circumstances surrounding the death. For this analysis, outcomes were categorized as infection-cause deaths, cardiovascular-cause deaths or other-cause deaths. Other patients were further classified as transfer to MHD, receipt of renal transplant, transfer to another facility or remaining on CPD.
Statistical analyses
Unless otherwise stated, continuous variables are expressed as the mean ± SD, and categorical variables are expressed as the number or percentage of each item. Comparisons among the three groups were analyzed via trend tests. Logarithmic conversion was conducted for such non-normal distribution variables as blood lead levels (log BLL), ferritin levels (log ferritin), residual renal Ccr (log renal Ccr) and iPTH levels (log iPTH).
To identify factors associated with log BLL or log iPTH, this investigation used simple linear regression analysis for all variables. All potential variables (P < 0.1) assessed with simple linear regression were entered into backward stepwise procedures. Variables with F values <4.0 were excluded from the final multiple linear regression models. To assess the relationship between degree of BLL and mortality, Kaplan-Meier curves were compared using the log rank test. The Cox multivariate proportional hazard model was applied to determine the significance of variables for predicting the 18-month mortality. The Cox proportional hazards model was applied to measure all potential variables and determine the significance of variables for predicting the all-cause 18-month mortality. The hazard ratios (HR) of death and 95% confidence intervals (95% CI) were obtained by the Cox proportional hazard model. Both the 'enter' and the 'conditional forward stepwise' methods were used for multivariate analysis. The PASS software (Power Analysis and Sample Size version 2005) was used to calculate the statistical power of this Cox regression model. The level of significance was set at P < 0.05. Data were analyzed using SPSS, version 12.0 for Windows 95 (SPSS, Inc., Chicago, IL, USA).
Results

Study population characteristics
We analyzed 315 CPD patients (115 men, 200 women) with a mean PD duration of 3.7 ± 3.0 years ( Figure 1) . Table 1 lists their clinical characteristics, including age, sex, body mass index and biological and haematological data. The mean patient age was 48.9 ± 14.1 years (range = 18-81 years). The mean serum albumin and blood haemoglobin level were 3.9 ± 0.5 g/dL (range = 2.2-5.0 g/dL) and 9.4 ± 1.6 g/dL (range = 4.7-18.8 g/dL), respectively. Table  1 also lists the patient characteristics for the three BLL g r ou p s . T he h i g h B L L g r o up ( n = 1 0 5 , m e d i a n BLL = 11.4 μg/dL [8.7, Fig. 1 . The Kaplan-Meier survival analysis for all-cause mortality of all chronic PD patients showed that the high BLL group patients had higher mortality than those in the middle and low BLL groups (log rank test, chisquare = 9.729, P = 0.008). P < 0.05 significant trends among the three study groups. nPNA, normalized protein nitrogen appearance. Patients who had hypertension mean they are taking antihypertensive drugs regularly or their blood pressure is >140/90 mmHg at least twice. Cardiovascular diseases included cerebrovascular disease, coronary arterial disease, congestive heart failure and peripheral vascular disease. Non-normal distribution data were presented as median (minimum, maximum).
Lead and mortality in chronic PD patientsence of viral hepatitis B antigen and viral hepatitis C antibody (data not shown).
Dialysate lead concentrations, peritoneal lead clearance and BLLs of CPD patients
The median lead level in all dialysate samples (n = 13) was 0.25 μg/dL (range = 0.00-0.70 μg/dL), far less than the American Association for Advancement of Medical Instrumentation Standard (<50 μg/L or 5 μg/dL). After the 4-h abdominal retention in the 13 CPD patients, the median lead level of the dialysates became 0.32 μg/dL (range = 0.00-0.83 μg/dL). Moreover, the median BLL was 7.3 μg/dL (range = 0.1-29.9 μg/dL) and the median C-BLL was 9.9 μg/dL (range = 0.1-37.4 μg/dL) in all the study subjects.
Determinants of BLLs in CPD patients
Simple linear regression analysis demonstrated that PD duration, smoking, WBC count, haemoglobin level, transferrin saturation, serum phosphate, log iPTH and log renal Ccr were potentially associated with log BLL (P < 0.1). Backward stepwise multiple linear regression analysis, after adjusting for related variables, showed that log renal Ccr and log iPTH were associated with log BLL (Table  2) . When BLLs were replaced with C-BLLs, similar results were noted ( Table 2) .
Kaplan-Meier survival analysis of 18-month mortality for CPD patients
At the end of the 18-month observation period, the following data were obtained: 37 patients (11.7%) died, including seven (seven out of 105, 6.7%) with low BLLs, 10 (10 out of 105, 9.5%) with middle BLLs and 20 (20 out of 105, 19.1%) with high BLLs. Of these patients, 22 (59.5%) died of CVD and 15 (40.5%) died of infection. A total of 233 patients completed the 18-month follow-up ( Figure 1 ). During this period, four patients were transferred to other outpatient PD units, 38 were transferred to MHD and three received kidney transplants. The median survival time of these patients PD, peritoneal dialysis; 95% CI, 95% confidence intervals; Ccr, creatinine clearance; BLL, blood lead level; nPNA, normalized protein nitrogen appearance. Patients who had hypertension mean they are taking antihypertensive drugs regularly or their blood pressure is >140/90 mmHg twice subsequently. Cardiovascular diseases included ischaemic heart disease, congestive heart failure, peripheral vascular disease and strokes.
was 11 months (range = 3-18 months). Kaplan-Meier survival analysis showed that the high BLL group had a higher mortality rate than the middle and low BLL groups (log rank test: P = 0.008; Figure 1 ).
Multivariate Cox regression analysis of 18-month mortality for CPD patients
Neither log BLL nor log C-BLL is a significant independent predictor of mortality in the 18-month all-cause mortality for CPD patients after potential variables are adjusted. However, when all potential variables related to mortality were assessed by the multivariate Cox proportional hazards model, the results demonstrated that, using the low BLL group as reference (HR = 1), high BLL (HR = 3.289, 95% CI = 1.251-13.514, P = 0.013) and middle BLL (HR = 2.082, 95% CI = 2.000-2.187, P = 0.006) were associated with increased HR for all-cause mortality for CPD patients (Table 3) . When the forward stepwise method of multivariate Cox regression analysis was also used to assess all potential variables, the results showed that, using the low BLLs group as reference, high BLL (HR = 3.745, 95% CI = 1.218-11.494, P = 0.001) and middle BLL (HR = 1.867, 95% CI = 1.618-2.567, P = 0.001) were associated with increased HR for allcause mortality for CPD patients (Table 4) . Similarly, when BLLs were replaced with high C-BLLs, using the low C-BLL group as reference, high C-BLLs (HR = 3.247, 95% C I = 1 . 0 4 7 -1 0 . 0 0 0, P = 0 . 0 1 4 ) a nd mi d dl e B L L (HR = 1.162, 95% CI = 1.064-1.275, P = 0.012) were associated with increased HR for all-cause mortality for these patients ( Table 4 ). The statistical power of high BLL or high C-BLL for all-cause mortality in multivariate Cox regression was estimated to be >0.90 with a sample size of 315.
Discussion
The study results first demonstrated that CPD patients with high BLLs have a significant trend of higher iPTH and phosphate levels and lower renal Ccr levels than patients with low or medium BLLs. On the contrary, CPD patients with low BLLs have a significant trend of lower iPTH and phosphate levels and higher renal Ccr levels than patients with medium or high BLLs. Moreover, BLL is negatively associated with RCcr and positively related to iPTH after related variables are adjusted. Each 10-fold increase in the renal Ccr resulted in a corresponding decrease of 0.08 μg/ dL in BLL, and each 10-fold increase in iPTH levels resulted in a 0.17 μg/dL increase in BLL. Hence, it seems reasonable to suggest that the cause of the high BLL could be related either to the effect of iPTH on releasing lead from bone or to the diminished renal clearance of lead. However, since this is a cross-sectional analysis, the possibility of BLLs influencing renal Ccr or iPTH levels cannot also be excluded. Further prospective randomized clinical trials are needed to clarify the possible causal effect between BLL and renal Ccr or iPTH in CPD patients.
The median BLL was 7.3 μg/dL [0.1, 29.9 μg/dL] in our study subjects, which is higher than that (5.8 μg/dL [1.6, 19.1 μg/dL]) of patients with chronic kidney disease (mean creatinine clearance = 35.1 ± 9.1 ml/min) [8] and that (4.8 μg/dL [1.6, 33.6 μg/dL]) of stroke patients with normal serum creatinine (n = 194) in Taiwan [20] . The results are similar to previous studies [12, 13] demonstrating elevated BLLs in patients with chronic renal dialysis. However, Van de Vyver et al. [21] showed that only 5% of a large group of dialysis patients had elevated bone lead (>14 μg/ g) by bone biopsy and that bone lead >14 μg/g is considered lead poisoning (EDTA mobilization test > 1000 μg) in the lead workers. Although a study [22] demonstrated that there is an association between BLL and bone lead contents, further study with an X-ray fluorescence method to assess bone lead of dialysis patients and healthy persons is required to clarify this issue. As low lead content (<10 μg/ L) in the dialysates, low lead clearance on PD and low BLL group patients with a higher residual renal Ccr were noted in this study, the increased BLLs in the CPD patients may be partially due to nearly complete loss of renal function and difficulty in removing lead during PD. Consequently, environmental exposure to lead, even at low levels, may increase BLLs in CPD patients. Lead and mortality in chronic PD patientsBy the end of the 18-month observation period, 37 (37 out of 315, 11.7%) patients had died. Mortality in the high BLL group (20 out of 105, 19.0%) was higher than that in the middle (10 out of 105, 9.5%) and low (seven out of 105, 6.7%) groups (log rank test in Kaplan-Meier survival analysis: P = 0.008). CVD was the major cause of death in these patients. The results are similar to our previous study on diabetic MHD patients [14] . However, mortality (7.6%) was lower, the follow-up period (12 months) was shorter and the sample size (n = 212) was smaller in the previous study [14] than in this study. Moreover, only diabetic MHD patients were included and no multivariate Cox proportional analysis was used to assess the HR of mortality in the previous study [14] . Hence, the current results draw a more definite conclusion about BLLs and mortality in patients undergoing long-term dialysis.
After adjusting for related variables, using the low BLL group as reference (HR = 1.00), high BLLs (HR = 3.745, 95% CI = 1.218-11.494, P = 0.001) and middle BLLs (HR = 1.867, 95% CI = 1.618-2.567, P = 0.001) were associated with increased HR for the 18-month all-cause mortality for CPD patients. The high BLL group patients had 3.7 times and the middle BLL group patients had 1.9 times the HR for mortality rates than that of the low BLL group patients after the 18-month follow-up period. We observed a trend of increased HR of mortality among the three study groups (P < 0.001). These results are similar to the findings of previous studies in the general population [1] [2] [3] . Recent epidemiological investigations [2, 3] have shown, in a nationally representative sample of the US population, that BLLs are associated with increased risk of death from all causes, CVD and cancer. A previous study [1] also found that individuals with baseline BLLs of 20-29 μg/dL had 46% increased all-cause mortality than the general population. Moreover, the statistical power of high BLL or high C-BLL for all-cause mortality in multivariate Cox's regression was estimated to be >0.90 with a sample size of 315 in this study. Consequently, environmental exposure to lead remains a significant determinant of mortality in the general population and in CPD patients and is a major public health problem that requires aggressive management.
Why high BLL is associated with a high mortality rate in CPD patients remains unknown. However, exposure to lowlevel lead may cause oxidative stress, inflammation [23] [24] [25] and overproduction of reactive oxygen species, which may in turn induce malnutrition, anaemia and atherosclerosis in ESRD patients [19, 26] . Therefore, it is possible that basal BLL degrees were related to the 18-month all-cause mortality of CPD patients in the current study. However, after adjustment for age, residual renal Ccr (the important factor to determine mortality of CPD patients) [27] and related variables, basal BLL degrees are still associated with mortality. Hence, other pathogeneses may exist between BLLs and mortality in CPD patients. Several other mechanisms may also underlie the toxic effects of lead, such as decreased NO synthesis [24] , induced hypertension [24, 25] , enhanced vascular reactivity to sympathetic stimulation and diminished DNA repair, which might be relevant for rapidly dividing cells in the inflamed arterial wall [28] . However, the definite pathogenesis of BLLs associated with mortality requires further investigation.
Because of the observational nature of this study, associations do not necessarily indicate causality. BLL reflects recent exposure to lead, although it is also influenced by long-term exposures through efflux of lead from bone stores [3] . Thus, it is unclear whether the adverse health effects of lead observed here were associated with current or cumulative exposures. Further bone lead assessment is needed to resolve this problem. Moreover, prospective studies are required to determine whether removal of sources of environmental lead exposure from CPD patients or aggressive treatment of hyperparathyroidism in these patients improves mortality. Because chelation therapy for low-level lead exposure has shown benefits in retarding progressive renal insufficiency in patients with chronic kidney disease [8] [9] [10] , it is reasonable to suggest chelation therapy for CPD patients with high BLLs if all other interventions are ineffective.
Conclusion
In conclusion, this is the first study demonstrating that BLLs relate to iPTH levels and residual renal Ccr. Degrees of BLL (or C-BLL) are associated with increased HR of the 18-month all-cause mortality of CPD patients. These results provide support for continued efforts to reduce environmental exposure to lead, aggressive treatment of hyperparathyroidism, maintenance of residual renal function and possible application of chelation therapy for these patients. However, further investigations are needed to clarify and confirm these observations.
